A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants with Opioid Use Disorder

Trial Identifier: 8062-CL-2003
Sponsor: Astellas Pharma Global Development, Inc.
Collaborator:
National Institute on Drug Abuse
Start Date: June 2020
Primary Completion Date: November 2020
Study Completion Date: November 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, KS Overland Park, KS, United States of America, 66212